Cargando…

Regulatory analysis on the medical use of ephedrine-related products in Taiwan

To prevent ephedrine-related products from being misused to produce amphetamine and/ or its analogs, there's a need for more effective and achievable regulatory mechanisms for the health, police, investigational, prosecution and judiciary authorities in Taiwan. This review was conducted to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wan-Nan, Wang, Li-Hsuan, Cheng, Hui-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322211/
https://www.ncbi.nlm.nih.gov/pubmed/29567216
http://dx.doi.org/10.1016/j.jfda.2017.11.002
_version_ 1784756242625855488
author Yu, Wan-Nan
Wang, Li-Hsuan
Cheng, Hui-Wen
author_facet Yu, Wan-Nan
Wang, Li-Hsuan
Cheng, Hui-Wen
author_sort Yu, Wan-Nan
collection PubMed
description To prevent ephedrine-related products from being misused to produce amphetamine and/ or its analogs, there's a need for more effective and achievable regulatory mechanisms for the health, police, investigational, prosecution and judiciary authorities in Taiwan. This review was conducted to evaluate the international and Taiwan's regulatory policies and management of medical ephedrine-related products through the corresponding information collected from international and Taiwan government agency authorities. The combat of illegal drugs should involve both supply and demand sides to be successful. Health authorities in Taiwan do not have the investigational power to manage the forbidden transformation, abusing and manufacture of the illegal drugs from ephedrine-related products. Take the judicial interventions in the United States and in Japan as the examples, the organizational cooperation in Taiwan can be one of the main key strategies to combat against illegal drugs from ephedrine-related products. It is necessary to integrate the judicial, police and health agencies to prevent the production of illegal drugs from the ephedrine-related products in Taiwan. The efforts and regulatory control measures should be integrated to speed up the collaboration between different government authorities. It might be achieved through reorganization involving Taiwan Food and Drug Administration.
format Online
Article
Text
id pubmed-9322211
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taiwan Food and Drug Administration
record_format MEDLINE/PubMed
spelling pubmed-93222112022-08-09 Regulatory analysis on the medical use of ephedrine-related products in Taiwan Yu, Wan-Nan Wang, Li-Hsuan Cheng, Hui-Wen J Food Drug Anal Review Article To prevent ephedrine-related products from being misused to produce amphetamine and/ or its analogs, there's a need for more effective and achievable regulatory mechanisms for the health, police, investigational, prosecution and judiciary authorities in Taiwan. This review was conducted to evaluate the international and Taiwan's regulatory policies and management of medical ephedrine-related products through the corresponding information collected from international and Taiwan government agency authorities. The combat of illegal drugs should involve both supply and demand sides to be successful. Health authorities in Taiwan do not have the investigational power to manage the forbidden transformation, abusing and manufacture of the illegal drugs from ephedrine-related products. Take the judicial interventions in the United States and in Japan as the examples, the organizational cooperation in Taiwan can be one of the main key strategies to combat against illegal drugs from ephedrine-related products. It is necessary to integrate the judicial, police and health agencies to prevent the production of illegal drugs from the ephedrine-related products in Taiwan. The efforts and regulatory control measures should be integrated to speed up the collaboration between different government authorities. It might be achieved through reorganization involving Taiwan Food and Drug Administration. Taiwan Food and Drug Administration 2017-12-02 /pmc/articles/PMC9322211/ /pubmed/29567216 http://dx.doi.org/10.1016/j.jfda.2017.11.002 Text en © 2018 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Review Article
Yu, Wan-Nan
Wang, Li-Hsuan
Cheng, Hui-Wen
Regulatory analysis on the medical use of ephedrine-related products in Taiwan
title Regulatory analysis on the medical use of ephedrine-related products in Taiwan
title_full Regulatory analysis on the medical use of ephedrine-related products in Taiwan
title_fullStr Regulatory analysis on the medical use of ephedrine-related products in Taiwan
title_full_unstemmed Regulatory analysis on the medical use of ephedrine-related products in Taiwan
title_short Regulatory analysis on the medical use of ephedrine-related products in Taiwan
title_sort regulatory analysis on the medical use of ephedrine-related products in taiwan
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322211/
https://www.ncbi.nlm.nih.gov/pubmed/29567216
http://dx.doi.org/10.1016/j.jfda.2017.11.002
work_keys_str_mv AT yuwannan regulatoryanalysisonthemedicaluseofephedrinerelatedproductsintaiwan
AT wanglihsuan regulatoryanalysisonthemedicaluseofephedrinerelatedproductsintaiwan
AT chenghuiwen regulatoryanalysisonthemedicaluseofephedrinerelatedproductsintaiwan